Defunct Company
Total Trials
11
As Lead Sponsor
10
As Collaborator
1
Total Enrollment
4,112
NCT02220244
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 31, 2013
Completion: Jan 31, 2018
NCT02220933
Effect of MD1003 in Spinal Progressive Multiple Sclerosis
NCT02961803
MD1003-AMN MD1003 in Adrenomyeloneuropathy
Phase: Phase 2/3
Start: Oct 31, 2014
Completion: Jun 30, 2017
NCT03114215
Effect of MD1003 in Amyotrophic Lateral Sclerosis
Phase: Phase 2
Start: Jun 29, 2016
Completion: Dec 31, 2017
NCT02967679
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Start: Dec 5, 2016
Completion: Mar 18, 2019
NCT02936037
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Start: Dec 31, 2016
Completion: Apr 23, 2020
NCT03552211
Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
Phase: N/A
Role: Collaborator
Start: May 30, 2018
Completion: Apr 30, 2019
NCT04252430
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
Phase: Phase 1
Start: Oct 9, 2019
Completion: Mar 17, 2020
NCT04252417
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
Start: Oct 11, 2019
NCT04168723
TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
Start: Nov 11, 2019
Completion: Mar 5, 2020
NCT04223232
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects
Start: Dec 10, 2019
Completion: Jan 22, 2020